Article Text

Download PDFPDF
Original research
Omeprazole-clopidogrel interaction and neurovascular complications after flow-diverter device placement
  1. Joshua S Catapano1,
  2. Visish M Srinivasan1,
  3. Andre A Wakim1,
  4. Jaclyn N Lundberg2,
  5. Caleb Rutledge1,
  6. Tyler S Cole1,
  7. Jacob F Baranoski1,
  8. Vance L Fredrickson1,
  9. Redi Rahmani1,
  10. Felipe C Albuquerque1,
  11. Andrew F Ducruet1
  1. 1Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA
  2. 2Department of General Medicine, Creighton University School of Medicine, Phoenix Health Sciences Campus, Phoenix, Arizona, USA
  1. Correspondence to Dr Andrew F Ducruet, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona AZ 85013, USA; neuropub{at}barrowneuro.org

Abstract

Background Omeprazole is a common proton pump inhibitor that interferes with the hepatic activation of clopidogrel and potentially reduces its platelet-inhibitory effect. Omeprazole has been shown to increase P2Y12 levels and adverse cardiovascular outcomes in patients treated with drug-eluting stents. However, omeprazole use among patients treated with flow-diverting stents for intracranial aneurysms has not been evaluated.

Methods All patients with placement of a flow-diverting device for treatment of an intracranial aneurysm at a tertiary institution from January 1, 2014, to December 31, 2018, were retrospectively analyzed. Inclusion criteria included documented clopidogrel administration, available P2Y12 levels, and thorough documentation of administration of other medications, including omeprazole.

Results A total of 138 patients met the inclusion criteria. Sixteen patients (12%) were receiving omeprazole and clopidogrel at treatment. P2Y12 reactivity was significantly greater in the omeprazole cohort (mean P2Y12 level, 250 P2Y12 reaction units (PRU)) than in the control cohort (mean P2Y12 level, 112PRU) (P<0.001). Furthermore, a greater proportion of patients had a P2Y12 level >180 PRU in the omeprazole cohort (14 of 16 [88%] vs 24 of 122 [20%]; P<0.001; OR [95% CI], 29 [6–134]).

Conclusion Omeprazole was associated with a significant increase in the mean P2Y12 reactivity level among patients with intracranial aneurysms treated with flow-diverting devices who received clopidogrel. However, receipt of omeprazole was not associated with an increased risk of ischemic events or stent stenosis. For neuroendovascular patients who are treated with a flow diverter while receiving clopidogrel, alternative gastrointestinal medication regimens should be considered.

  • aneurysm

Data availability statement

No additional data are available to share.

Statistics from Altmetric.com

Data availability statement

No additional data are available to share.

View Full Text

Footnotes

  • Contributors All authors made substantial contributions to the conception or design of the work or the acquisition, analysis, or interpretation of data for the work; drafted the work or revised it critically for important intellectual content; provided final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests Dr. AFD is a consultant for Medtronic, Stryker, Koswire, Penumbra, and Cerenovus. Drs. FCA and AFD are on the editorial board for the Journal of NeuroInterventional Surgery.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.